First pan-RAS inhibitor shows vascular signals but no cardiac endpoint data yet
A review finds peripheral oedema and hypertension documented with daraxonrasib, but no published cardiac endpoint data at Phase 3 scale.
Tag: peripheral oedema
POPULAR NEWS
-
Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant
-
Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast
-
ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth
-
Systematic review maps sustainability tensions in offshore wind development